Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery with the ankle implant Episealer® Talus in Belgium has been scheduled. In February 2022, Episurf Medical communicated that reimbursement coverage for Episealer® Talus in Belgium had been obtained.

"We have for been offering our Episealer® Knee technology to our Belgian customers for some time, and we are now pleased to also be able to offer our Episealer® Talus technology in the country. The first surgery is always an important milestone", says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

https://news.cision.com/episurf/r/first-episealer--talus-surgery-planned-in-belgium,c3553169

https://mb.cision.com/Main/14691/3553169/1569043.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English